Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

Now Viewing

EP: 1.Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

EP: 2.Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

EP: 3.Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

EP: 4.Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

EP: 5.Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

EP: 6.Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

EP: 7.Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

EP: 8.New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

Theresa Boyle, MD, PhD, molecular pathologist and assistant professor at Moffitt Cancer Center, discusses the role of concurrent molecular testing in lung cancer.

The role of liquid biopsy has grown significantly in lung cancer and is often utilized before tissue-based testing, says Boyle. The results of plasma-based testing can be obtained quickly and inform targeted therapy options for patients, Boyle explains. Although similar molecular markers can be identified with liquid and tissue biopsies, tissue-based testing is often reserved for confirmation or to ensure a mutation was not missed with the liquid biopsy, Boyle says.

For example, if a liquid biopsy does not reveal a driver mutation in a patient with lung adenocarcinoma who has never smoked, tissue testing is indicated to ensure nothing was missed, Boyle says. In some cases, patients may not have enough circulating tumor DNA for the liquid biopsy to identify an aberration, so tissue-based testing is often needed, concludes Boyle.